Cesia

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cesia

What is Cesia? Identity and Facts Overview

Property Description
Active ingredient Desogestrel and Ethinyl Estradiol
Form Tablet (oral)
Pharmacological class Combined Oral Contraceptive
Common use Prevention of pregnancy (Birth control)
Origin Synthetic (synthetic progestin and estrogen)

Defining Cesia: Classification and Composition

Cesia is classified as a combined oral contraceptive product, administered via the oral route in tablet form, available only with a prescription. This medication belongs to the pharmacological class of Combined Contraceptives due to its composition of two distinct types of synthetic hormones: a progestin and an estrogen. The two active ingredients are Desogestrel (a synthetic progestin) and Ethinyl Estradiol (a synthetic estrogen). These core active components define the drug's action and identity, with the formulation being chemically equivalent to other generics such as Apri and Enskyce.

Core Active Components and Purpose

The combination of Ethinyl Estradiol and Desogestrel achieves the drug's essential therapeutic purpose, which is the prevention of pregnancy. This function provides women of reproductive age with a reliable form of birth control when used consistently. Desogestrel is characterized as a third-generation progestogen, a categorization reflecting its modern chemical structure and pharmacological profile. The efficacy of this combined hormonal drug class is established for its success rate in fertility management.

Type and Categorization of Hormones

Cesia is a combination product that utilizes its dual hormonal components to achieve its effect. The fundamental action of this therapy is to suppress gonadotropins, which subsequently inhibits the critical reproductive event of ovulation. This primary mechanism is the basis for how the combined product delivers its intended contraceptive effect, differentiating it from progestin-only contraceptives.

What side effects are possible with Cesia?

Possible side effects and safety information

Official regulatory documents classify adverse reactions for Cesia (desogestrel/ethinyl estradiol) by frequency, distinguishing between common, expected reactions and rare, serious safety concerns. This medicine's safety profile is formally structured around established risks associated with the combined oral contraceptive class, as documented by authorities such as the FDA and EMA.


Documented Adverse Reactions and Frequencies

Adverse reactions are grouped by the physiological system affected, including Gastrointestinal (e.g., nausea, vomiting, abdominal pain), Nervous System (headache, migraine), Psychiatric (depressed mood, changes in libido), and Reproductive System (breast tenderness, breakthrough bleeding). Frequencies, based on regulatory classification, generally include:

  • Common (may affect up to 1 in 10 users): Headache, nausea, breast tenderness/enlargement, and increase in body weight.
  • Uncommon (may affect up to 1 in 100 users): Vomiting, fluid retention, nervousness, migraine, and rash.

Serious Safety Concerns and Restrictions

The label documents serious adverse events that, while rare, are clinically significant. This includes the risk of Venous and Arterial Thromboembolic Events (VTE/ATE) such as Deep Vein Thrombosis, Pulmonary Embolism, Stroke, and Myocardial Infarction. The risk of VTE is officially stated to be highest during the first year of use and when restarting the medication after a break of four weeks or longer.

Safety is formally restricted by several contraindications outlined in official labeling. Cesia should not be used in individuals with a current or past history of thromboembolic disorders, severe hepatic impairment, or known or suspected hormone-dependent cancers such as breast cancer. Furthermore, the risk of serious cardiovascular adverse reactions is elevated by smoking, particularly in women over the age of 35, according to regulatory warnings.

Overdose and Emergency Response

Overdose Profile and Emergency Action

Acute overdose with Cesia (Desogestrel and Ethinyl Estradiol) is generally documented as having low acute toxicity and is typically not associated with serious or life-threatening outcomes. This classification is based on official prescribing information for combined oral contraceptives.


Documented Manifestations

The reported clinical presentations following overexposure are primarily non-serious, hormonal effects. These include common gastrointestinal signs such as nausea and vomiting. A specific manifestation is vaginal bleeding, which is often described as withdrawal bleeding. In young, pre-pubertal females, slight vaginal bleeding is a specifically noted clinical sign of overexposure.


Mandated Emergency Action

It is required to seek immediate medical attention for any suspected overdose. Urgent emergency treatment must be sought if severe symptoms develop, such as those related to the drug's known vascular risks, including severe chest pain or sudden severe headache. No specific antidote is known for this overdose. Treatment, according to regulatory guidance, is symptomatic and supportive, and may involve monitoring of vital signs and laboratory tests.

Therapeutic Uses of Cesia

What Cesia Treats: Main Uses and Benefits

Cesia is a combined oral contraceptive that may provide support for the prevention of pregnancy in women of reproductive age. The medication is also commonly used in situations involving symptomatic discomfort related to the reproductive cycle, and it is relevant when supportive symptom management is appropriate. The medication is commonly used to help with symptom clusters that may be related to conditions such as heavy menstrual bleeding (menorrhagia) and painful periods (dysmenorrhea).


Managing Menstrual Distress and Supportive Care

The medication may assist with managing symptom clusters that interfere with daily comfort, such as painful periods and excessive flow. It is applied across therapeutic domains where additional symptomatic support is needed, and contributes to easing the overall symptom load associated with menstrual distress. It assists with maintaining day-to-day comfort by supporting a more regular menstrual cycle pattern, which helps patients cope more steadily with symptom fluctuations.

Cesia is also relevant for managing pelvic pain and other discomfort associated with conditions like endometriosis, and it is used in the supportive management of acne in certain patients.


Quick Fact: Condition Focus: Managing Menstrual Pain

Cesia is commonly used to help manage the severity of dysmenorrhea (painful periods), contributing to support general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility Rules and Restrictions

Cesia (desogestrel/ethinyl estradiol) is a combined oral contraceptive restricted to use by post-pubertal women of reproductive age who do not possess specific severe risk factors, as defined by regulatory authorities like the FDA and EMA.

Eligibility Status Applicable Populations/Conditions (Summary)
Allowed Use Women of reproductive age for pregnancy prevention; Post-pubertal females.
Not Recommended Women who are breastfeeding (due to potential reduction in milk quality/quantity).
Contraindicated Pregnancy; History of or current blood clots (VTE/ATE); Uncontrolled hypertension; Diabetes with vascular complications; Liver tumors or active liver disease; Hormone-sensitive cancers (e.g., breast cancer); Women over 35 years old who smoke; Migraine with aura; Undiagnosed genital bleeding.

Eligibility is also temporarily restricted during periods of prolonged immobilization or prior to and following major surgery due to increased thromboembolic risk. The drug is not indicated for use before menarche or in the geriatric population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cesia, a combined oral contraceptive, is subject to officially documented pharmacokinetic and pharmacodynamic interactions. These interactions are categorized based on their mechanism and the resulting restriction defined in regulatory labeling.

Documented Interaction Restrictions

Co-administration with specific medicinal products is formally contraindicated. These include Hepatitis C drug regimens containing Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir, and products containing Glecaprevir/Pibrentasvir. The label also prohibits co-administration with oral Tranexamic Acid due to an increased risk of thrombotic events, and Fezolinetant.

Pharmacokinetic Interaction Patterns

The most frequent documented interaction involves hepatic enzyme systems. Enzyme-inducing agents, such as Rifampicin and certain anticonvulsants (e.g., Phenytoin), may significantly decrease the plasma concentrations of the contraceptive hormones (desogestrel/ethinyl estradiol). Conversely, substances like Ascorbic Acid (Vitamin C) may cause an increase in the exposure of ethinyl estradiol by inhibiting its clearance. The label notes that certain antibiotics may potentially reduce contraceptive efficacy by altering enterohepatic recirculation.

Timing rules are required for certain contraindicated combinations; Cesia must be discontinued prior to initiating the Hepatitis C regimens and may be restarted approximately two weeks after completion of the antiviral treatment.

Mechanism of Action

Cesia is a combination oral contraceptive containing the progestin desogestrel (as a prodrug for etonogestrel) and the estrogen ethinyl estradiol. The primary action occurs in the hypothalamic-pituitary-ovarian axis. Etonogestrel acts as an agonist for the intracellular progesterone receptor (PR), while ethinyl estradiol is an agonist for the estrogen receptor (ER). This dual agonism exerts negative feedback on the hypothalamus, suppressing the pulsatile release of Gonadotropin-releasing hormone (GnRH). The resulting decrease in GnRH signaling attenuates the secretion of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH) from the anterior pituitary gland. The systemic reduction of FSH prevents follicular development within the ovary, while the suppression of the LH surge inhibits the molecular and cellular cascade required for ovulation. Furthermore, etonogestrel modifies the cervical environment by increasing the viscosity of the cervical mucus, establishing a physical barrier. The combined hormonal action results in a system-level state of anovulation and decreased gamete transport.

Dosage and Administration Information

How to Use Cesia: Official Administration Guidelines

Cesia is a combined oral contraceptive that is used according to a continuous, 28-day cyclic regimen. The medicine is administered via the oral route (by mouth), with the required dose being one tablet taken daily.


Regimen Structure and Timing

Its official use is strictly sequenced, involving the intake of 21 active hormone tablets immediately followed by 7 inert (placebo) tablets. A new 28-day pack is started immediately after the previous one is completed, with no gap days between cycles. For maximum consistent exposure, the tablets must be taken at approximately the same time each day. The tablet may be taken with or without food.

Initiation and Special Conditions

Regimen initiation follows one of two common starting methods: the Day 1 Start (beginning on the first day of menses) or the Sunday Start. If the Sunday Start is utilized, back-up non-hormonal contraception is required for the first 7 days of the initial cycle.

Missed Dose Management is a documented procedural step of the administration protocol, with specific instructions varying based on the number of active tablets missed and the week of the cycle. For special populations, postpubertal adolescents use the same adult dosing regimen, and postpartum use is generally initiated 4 to 6 weeks after delivery in non-breastfeeding patients.

Recent Clinical Evidence

Cesia: Recent Clinical Evidence

Cesia is a prescription combination oral contraceptive, containing drospirenone (a progestin) and ethinyl estradiol (an estrogen). Clinical research has primarily evaluated its role in three specific areas:


1. Contraceptive Efficacy

Clinical trials have consistently studied the effectiveness of the drospirenone/ethinyl estradiol combination for preventing pregnancy. Studies have reported that when taken as directed, the combination provides a high degree of contraceptive protection. Data from various international and region-specific trials have generally reported low Pearl Index values, indicating robust efficacy.

2. Non-Contraceptive Benefits

In addition to its primary use, research has examined the combination’s potential to affect certain non-contraceptive outcomes. This includes:

  • Acne Vulgaris: Studies have explored the combination’s use in treating moderate acne in women who also desire contraception. Findings suggest an association between use and a reported improvement in acne symptoms.
  • Premenstrual Dysphoric Disorder (PMDD): Clinical data has been collected to assess whether the combination may help alleviate the severe emotional and physical symptoms associated with PMDD in the 24/4 regimen.

3. Safety Profile and Specialized Research

Safety studies and systematic reviews have focused on characterizing the tolerability of this combination, particularly its drospirenone component, which has antimineralocorticoid and antiandrogenic properties. The most frequently reported adverse events in trials were generally mild and temporary, including headache and nausea.

Research continues to examine the long-term safety of all hormonal contraceptives, including the potential for increased risk of serious adverse events such as venous thromboembolism (blood clots). The evidence suggests the overall safety profile of the drospirenone/ethinyl estradiol combination is comparable to that of other available combined oral contraceptives.

Key Studies & References

  1. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen
  2. Combined hormonal contraception and the risk of venous thromboembolism: a guideline (American Society for Reproductive Medicine)

Frequently Asked Questions (FAQ)

Common questions about Cesia (FAQ)


Q: Is Cesia the same as other similar medications I see advertised?

Regulatory guidance on combined oral contraceptives states that a generic version must be chemically equivalent to the brand-name product. This means that generic products, which may be advertised, must contain the exact same active ingredients and strength as Cesia to be approved.

Q: How quickly does Cesia start working?

Official prescribing instructions recommend using a non-hormonal back-up method for the first seven days of the initial cycle when using certain starting methods. This procedural step is put in place to help ensure appropriate coverage, as specified in official instructions.

Q: What happens if I miss a dose of Cesia?

Missed dose management is a formal procedure that is detailed in the official patient information provided with the drug. The specific steps recommended depend on factors like the number of active tablets missed and the timing within the 28-day cycle.

Q: Can Cesia cause weight changes?

Official safety information documents that an increase in body weight is a common adverse reaction that may be experienced by users. According to regulatory classifications, this effect may affect up to 1 in 10 users.

Q: Will taking Cesia interfere with my sleep?

The official adverse reaction list for this medication includes nervousness as an uncommon reaction. This is a nervous system effect that is formally documented by regulatory authorities.

Q: Is alcohol safe to consume while using Cesia?

Regulatory interaction information classifies alcohol consumption (ethanol) with the active ingredients of Cesia as a minor drug interaction.

Q: Are there any foods or drinks to avoid when taking Cesia?

Official drug interaction guidelines warn that certain foods, specifically grapefruit or grapefruit juice, may potentially affect the body's absorption of the medication. This is documented to provide information on how the body handles the medicine.

Q: Does Cesia affect hair growth or loss?

Clinical research has explored the non-contraceptive benefits of this combination, including managing certain symptoms associated with high male hormones. These symptoms include acne and unwanted hair growth.

Q: Does Cesia impact fertility after stopping the medication?

Studies and official information indicate that the use of combined oral contraceptives does not affect a woman's long-term fertility after the medication is discontinued. The return of the natural menstrual cycle and ovulation may occur quickly after stopping the drug.

Q: How does Cesia relate to hormones naturally made by the body?

Cesia contains synthetic hormones that work by suppressing the release of natural hormones, such as Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH). This suppression is the primary mechanism that prevents ovulation.

Q: Does Cesia interact with antibiotics?

Official labeling notes that the effectiveness of the contraceptive may be lowered by certain antibiotics. This is due to a potential change in the body’s process for handling the hormones.

Q: What happens to the drug in the body?

This medicine is processed primarily in the liver and intestinal lining (metabolism). Its components are then eliminated from the body mainly through urine and feces, as described in the official pharmacokinetics section.

Q: Is it common to have nausea when first starting Cesia?

Nausea is classified as a common adverse reaction in official documents. Patient information notes that this side effect is often experienced, particularly during the first few months of use.

Q: What is the difference between brand-name Cesia and its generic equivalent?

The FDA requires that a generic version be chemically identical to the brand-name drug and also perform the same way in the body (a concept called bioequivalence). This means they contain the same active ingredients in the same strength.

Q: If I have a history of migraines, can I still use Cesia?

Official eligibility rules specify that the presence of a migraine with aura is a contraindication, meaning the drug should not be used in this specific condition. Migraine without aura is listed as an uncommon adverse reaction.

Q: Can men or non-pregnant people use Cesia?

Official documentation restricts the use of this drug to post-pubertal women of reproductive age. Its use is indicated for the prevention of pregnancy.

Q: Why is my doctor asking about my family history before prescribing Cesia?

Family history questions are used by healthcare providers to screen for an inherited tendency toward serious conditions. This is often focused on the risk of blood clots (venous thromboembolism), which is a key safety concern for this class of medicine.

Q: What are the long-term effects of using Cesia?

Long-term research and systematic reviews focus on characterizing the drug's safety profile. This includes examining the potential for an increased risk of serious adverse events such as blood clots (VTE/ATE).

Q: How is Cesia different from combination medications for the same condition?

Cesia is officially classified as containing a third-generation progestin (desogestrel). This specific categorization distinguishes it from other combination products that utilize progestins from earlier or later generations.

Q: Why is there a Patient Information Sheet (PIL) specifically for Cesia?

The Patient Information Sheet (or Medication Guide) is a regulatory requirement for this class of drug. It ensures patients receive essential, up-to-date, factual, and non-promotional details on proper use, missed dose procedures, and serious risks.

Q: Does Cesia change the results of any common lab tests?

Official prescribing information documents that the medicine may interfere with the results of certain laboratory tests. These can include tests related to blood clotting factors or thyroid function.

Q: How long after stopping Cesia can I try to become pregnant?

Studies indicate that the return of the natural menstrual cycle and ovulation may occur quickly after stopping the drug, meaning that the potential for pregnancy may return quickly upon discontinuation.

How should Cesia be stored and disposed of?

Storage and Disposal Instructions for Cesia

Cesia (desogestrel/ethinyl estradiol) tablets must be stored according to regulatory specifications to maintain stability and effectiveness.


Official Storage Requirements

Requirement Specifics
Temperature Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F). Temporary excursions between 15 C and 30 C are permitted.
Protection Keep the medicine in its original container and protect it from light and moisture.
Safety Must be stored out of the sight and reach of children.

Disposal Protocol

Unused or expired Cesia should not be flushed down the toilet or poured down a sink. Disposal must follow regulatory guidelines. It is recommended to use a drug take-back program. If one is unavailable, the medicine should be mixed with an unappealing substance, placed in a sealed bag or container, and discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cesia found in:

A-Z Index: